Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab in pMN, IM-FSGS, and MCD
NCT07861113Phase 2Not yet recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of sibeprenlimab in primary membranous nephropathy (PMN), focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sibeprenlimab
03
Conditions
primary membranous nephropathy (PMN)focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT07861113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07861113.